

CLAIMS

1. Combinations of an antiemetic agent with an enkephalinase inhibitor.
- 5 2. The combination according to claim 1, wherein said anti emetic is a 5-HT₃ receptor antagonist.
3. The combination according to claim 2, wherein said 5-HT₃ receptor antagonist is selected from the group consisting of ondansetron and granisetron.
- 10 4. The combination according to anyone of the preceding claims wherein said enkephalinase inhibitor is selected from the group consisting of racecadotril and dexecadotril.
5. A pharmaceutical composition comprising the combination according to anyone of the preceding claims, and a pharmaceutically
15 acceptable vehicle or excipient.
6. The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition is for simultaneous, separate or sequential administration of said enkephalinase inhibitor and said antiemetic agent.
7. The pharmaceutical composition according to claim 5 or 6,
20 wherein said pharmaceutical composition is suitable for oral administration.
8. The pharmaceutical composition according to any one of claims 5 to 7, wherein said pharmaceutical composition is in the form of tablets, capsules or granulated powder.
9. The pharmaceutical composition according to anyone of claims 5
25 to 8, wherein said pharmaceutical composition of the invention comprises between 50 and 100 mg of said enkephalinase inhibitor per dosage unit for adults and corresponding doses according to body weight for children and babies.
10. The pharmaceutical composition according to anyone of claims 5
30 to 9 wherein said pharmaceutical composition comprises between 1 and 8 mg of a 5-HT₃ antagonist per dosage unit for adults and corresponding doses according to body weight for children and babies.
11. The pharmaceutical according to anyone of claims 5 to 10 wherein said pharmaceutical composition comprises between 2 and 8 mg of

ondansetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

12. The pharmaceutical composition according to anyone of claims 5 to 11, wherein said pharmaceutical composition comprises between 1 and 4 mg of granisetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

13. The pharmaceutical composition according to anyone of claims 5 to 12, wherein said pharmaceutical composition comprises the combination of the invention in the same dosage unit.

14. Use of the combination according to anyone of claims 1 to 4 in the preparation of a pharmaceutical composition according to anyone of claims 5 to 13 for the treatment of acute gastroenteritis.

15. Use of the combination according to anyone of claims 1 to 4 in the preparation of a pharmaceutical composition according to anyone of claims 5 to 13 for the treatment of acute diarrhoea associated with emesis.

16. Use according to claim 15, wherein said diarrhoea is chemotherapy-induced diarrhoea, carcinoid diarrhoea, traveller's diarrhoea, diarrhoea elicited by various bacteria, viruses or parasites.

17. Use according to anyone of claims 14 to 16, wherein said treatment comprises oral administration, preferably two to four times a day.

18. Use according to anyone of claims 14 to 17, wherein said treatment comprises administration of the composition according to anyone of claims 5 to 13 two to four times a day.

19. Use according to anyone of claims 14 to 18, wherein said combination comprises dexecadotril and ondansetron for the preparation of a pharmaceutical composition for the treatment of acute gastroenteritis by simultaneous, separate or sequential oral administration of the active ingredients.